The FDA-cleared BIOFIRE Blood Culture Identification 2 (BCID2) Panel is a fast, comprehensive diagnostic test for positive blood cultures. It quickly identifies a broad range of pathogens and antimicrobial resistance genes related to bloodstream infections, enabling clinicians to manage therapy more effectively.1,2
Gram-positive Bacteria
- Enterococcus faecalis
- Enterococcus faecium
- Listeria monocytogenes
- Staphylococcus spp.
- Staphylococcus aureus
- Staphylococcus epidermidis
- Staphylococcus lugdunensis
- Streptococcus spp.
- Streptococcus agalactiae
- Streptococcus pneumoniae
- Streptococcus pyogenes
Gram-negative Bacteria
- Acinetobacter calcoaceticus-baumannii complex
- Bacteroides fragilis
- Enterobacterales
- Enterobacter cloacae complex
- Escherichia coli
- Klebsiella aerogenes
- Klebsiella oxytoca
- Klebsiella pneumonia group
- Proteus spp.
- Salmonella spp.
- Serratia marcescens
- Haemophilus influenzae
- Neisseria meningitidis
- Pseudomonas aeruginosa
- Stenotrophomonas maltophilia
Yeast
- Candida albicans
- Candida auris
- Candida glabrata
- Candida krusei
- Candida parapsilosis
- Candida tropicalis
- Cryptococcus (C. neoformans/C. gattii)
Antimicrobial Resistance Genes
- Carbapenemases
- IMP
- KPC
- OXA-48-like
- NDM
- VIM
- Colistin Resistance
- mcr-1
- ESBL
- CTX-M
- Methicillin Resistance
- mecA/C
- mecA/C and MREJ (MRSA)
- Vancomycin Resistance
- vanA/B
Technology: Multiplex PCR-based molecular diagnostics (syndromic approach)
Format: Single, self-contained, freeze-dried reagent pouch
Sample Type: Positive blood cultures
Result Time: In about one hour
Ease of Use: Automated workflow from sample to result, requiring minimal hands-on time
The fast identification provided by the BCID2 Panel is crucial for effective clinical management. By delivering results in about an hour, it allows clinicians to quickly identify the cause of bloodstream infections and adjust therapy, which can help improve patient outcomes and survival.3,4,5 The detection of key resistance genes informs treatment decisions, helping to ensure the most appropriate and effective antimicrobials are utilized.1,2
Related Products
- Donnars A, Mahieu R, Declerck C, et al. BIOFIRE® Blood Culture IDentification 2 (BCID2) panel for early adaptation of antimicrobial therapy in adult patients with bloodstream infections: a real-life experience.
- Zhang D, et al. Critical Care Medicine 2015;43(10):2133-2140
- Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61(7):1071-1080.
- Pérez-Lazo G, Valle-Mendoza JD, Sandoval-Ahumada R, et al. Impact of adding a rapid PCR-based blood culture identification panel to the antimicrobial stewardship program of patients with febrile neutropenia in a Peruvian referral hospital. Antibiotics (Basel). 2023;12(4):648.
- Britt NS, Khader K, He T, et al. Examining the clinical impact of rapid multiplex polymerase chain reaction-based diagnostic testing for bloodstream infections in a national cohort of the Veterans Health Administration. Pharmacotherapy. 2023;43(1):24-34.
Contact Us
Eager to advance your biothreat detection and infectious disease diagnostic capabilities? Connect with us to discuss how BioFire can help strengthen your preparedness and accelerate your response in critical situations.